Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Medicine|August 17, 2018
Reduction in the incidence of pneumonia in elderly patients after hip fracture surgery: An inpatient pulmonary rehabilitation programShih-Chieh Chang, Jiun-I Lai, Mei-Chin Lu, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 2, 2022
CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancerChih-Yi Lin, Chung-Jen Yu, Chun-Yu Liu, et al.
Cancer Research and Treatment|December 31, 2025
Platinum and 5-FU Salvage Therapy for Severe Liver Crisis in Metastatic Breast Cancer: Efficacy and Analysis of Prognostic FactorsI-Wei Ho, Jiun-I Lai, Chun-Yu Liu, et al.
Bioorganic & Medicinal Chemistry Letters|June 27, 2017
Cyclic tetrapeptide HDAC inhibitors as potential therapeutics for spinal muscular atrophy: Screening with iPSC-derived neuronal cellsJiun-I Lai, Luke J Leman, Sherman Ku, et al.
The Oncologist|March 10, 2025
Efficacy of atezolizumab combined with platinum and etoposide in the treatment of extrapulmonary neuroendocrine carcinomaI-Wei Ho, Nai-Jung Chiang, Jiun-I Lai, et al.
The Journal of Biological Chemistry|December 16, 2018
Transcriptional profiling of isogenic Friedreich ataxia neurons and effect of an HDAC inhibitor on disease signaturesJiun-I Lai, Daniel Nachun, Lina Petrosyan, et al.
Journal of the Chinese Medical Association : JCMA|December 3, 2014
Early changes of the anemia phenomenon in male 100-km ultramarathonersYu-Hui Chiu, Jiun-I Lai, Shih-Hao Wang, et al.
Journal of Cancer|February 24, 2025
Addition of Bevacizumab to Vinorelbine-Platinum combination is efficacious in Heavily Pretreated HER2-Negative Metastatic Breast CancerI-Wei Ho, Yi-Ru Tseng, Chun-Yu Liu, et al.
Medical Oncology (Northwood, London, England)|September 30, 2022
IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic targetChih-Yi Lin, Chung-Jen Yu, Chia-I Shen, et al.
Translational Oncology|August 12, 2019
Concomitant Genetic Alterations are Associated with Worse Clinical Outcome in EGFR Mutant NSCLC Patients Treated with Tyrosine Kinase InhibitorsShih-Chieh Chang, Yi-Chun Lai, Cheng-Yu Chang, et al.
Pageof 6